title: Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation.
abstract: Twenty asthmatic children and 48 patients with severe psychomotor retardation were inoculated intranasally with trivalent cold-adapted recombinant (CR) influenza vaccine containing CR-125 (H1N1), CR-159 (H3N2) and CRB-117 (B). The vaccinees were mostly seropositive. Severe adverse reactions or asthmatic attacks were not observed, but 7 (15%) of 48 vaccinees with severe psychomotor retardation developed mild to moderate fever. Significant antibody responses in hemagglutination-inhibition tests were demonstrated in 33 (49%) vaccinees to CR-125, 20 (29%) to CR-159 and 8 (12%) to CRB-117. Two nosocomial outbreaks of influenza were observed in the subsequent winter. During an outbreak with H3N2 in one ward of severe psychomotor retardation patients, 2 (11%) of 18 vaccinees became infected compared with 10 (48%) of 21 placebo controls in the same ward (P < 0.05). In the other outbreak, with influenza B virus, 2 (14%) of 14 vaccinees and 13 (52%) of 25 controls in the ward for asthmatic children were infected (P < 0.05). The results indicate that trivalent CR vaccine is safe and effective against nosocomial outbreaks of influenza.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Ueda
authors.forename: C
authors.initials: C
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Kusuhara
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Tokugawa
authors.forename: R
authors.initials: R
authors.lastname: Shibata
authors.forename: S
authors.initials: S
authors.lastname: Nishima
authors.forename: N
authors.initials: N
authors.lastname: Yamane
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D001249:Asthma / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000517:prevention & control*; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control*; D007326:Institutionalization; D009975:Orthomyxoviridae / Q000276:immunology; D011596:Psychomotor Disorders / Q000276:immunology; D014611:Vaccination; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines